Clinical trials: Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis
This study is conducted to evaluate the safety and tolerability of the drug product sNN0029, containing the growth factor VEGF165, when administered directly into one of the fluid filled cavities in the brain using an implanted…
- Trial name
- NCT00800501
- Testing
- sNN0029
- Where
- Belgium
- Volunteers
- 18 people
- Sponsor
- Newron Sweden AB
Amyotrophic Lateral Sclerosis
Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2
The primary objective is to evaluate in ALS patients the regulatory T cell early response to two low-doses of IL-2 at 1 and 2 MIU per day after one course of 5 consecutive days comparatively to placebo.
- Trial name
- IMODALS (NCT02059759)
- Testing
- 1.0 MIU IL-2 per day, 2.0 MIU IL-2 per day
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Amyotrophic Lateral Sclerosis, ALS
Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)
The goal of this study is to evaluate the safety and feasibility of IVIg administration in conjunction with primary motor cortex BBB opening using the Next Generation Dome Helmet (NGDH) FUS in adult participants with ALS.
- Trial name
- ALSFUS003 (NCT07193953)
- Testing
- Next Generation Dome Helmet Focused Ultrasound, Intravenous immunoglobulin (IVIG), 10% solution for infusion, Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Sunnybrook Health Sciences Centre
Muscular Dystrophy, Duchenne, Orthotic Devices
The Effect of a Muscle-mimicking, Fabric-type Shoulder Orthosis on Functional Movements of the Upper Limb in Patients With Neuromuscular Disorder
The goal of this clinical trial is to investigate the effect of a muscle-mimicking, fabric-type shoulder orthosis on functional movements of the upper limb in patients with neuromuscular disorder.
- Conditions
- Muscular Dystrophy, Duchenne, Orthotic Devices, Upper Extremity, Neuromuscular Diseases (NMD)
- Trial name
- NCT06363357
- Testing
- Shoulder orthosis
- Where
- South Korea
- Volunteers
- 8 people
- Sponsor
- Seoul National University Hospital
Amyotrophic Lateral Sclerosis
Intravenous Transplantation of Mesenchymal Stem Cell in Patients With ALS
ALS is a debilitating disease with varied etiology characterized by rapidly progressive weakness, muscle atrophy and fasciculations, muscle spasticity, difficulty speaking (dysarthria), difficulty swallowing (dysphagia), and…
- Trial name
- NCT01759797
- Testing
- intra venous injection of stem cell
- Where
- Iran
- Volunteers
- 6 people
- Sponsor
- Royan Institute
Amyotrophic Lateral Sclerosis
Effectiveness of Expiratory Muscle Strength Training for Improving Communication in ALS
A tele-health treatment study for individuals with early stage ALS with the aim to improve communication, cough response, and respiratory strength.
- Trial name
- NCT05003167
- Testing
- Expiratory Muscle Strength Training (EMST-150)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Purdue University
Amyotrophic Lateral Sclerosis
Triumeq in Amyotrophic Lateral Sclerosis
To determine if Triumeq improves survival in Amyotrophic Lateral Sclerosis (ALS) compared with placebo
- Trial name
- LIGHTHOUSE II (NCT05193994)
- Testing
- Dolutegravir, Abacavir and Lamivudine
- Where
- 28 sites in Australia, Ireland and 6 more
- Volunteers
- 419 people
- Sponsor
- Macquarie University, Australia
Amyotrophic Lateral Sclerosis
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis
The primary objective of this study is to evaluate the safety, tolerability of single-ascending doses of BIIB100 in adults with amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT03945279
- Testing
- BIIB100
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
The CENTAUR trial was a 2:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and efficacy of AMX0035 for the treatment of ALS.
- Conditions
- Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Diseases, Neurodegenerative Diseases
- Trial name
- CENTAUR (NCT03127514)
- Testing
- AMX0035
- Where
- 25 sites in United States
- Volunteers
- 137 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Amyotrophic Lateral Sclerosis, Muscular Dystrophy
Innovative Ultrasound Technology in Neuromuscular Disease
This study is utilizing ultrasound measurement to measure neuromuscular disease status in adult patients. The hypothesis is the by quantifying ultrasound data, it is possible that ultrasound can be utilized as a tool to determine…
- Conditions
- Amyotrophic Lateral Sclerosis, Muscular Dystrophy, Radiculopathy, Myopathy
- Trial name
- AQUIRe (NCT02104921)
- Where
- United States
- Volunteers
- 223 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Amyotrophic Lateral Sclerosis, ALS Functional Ration Scale
Tamoxifen Treatment in Patients With Motor Neuron Disease
The aim of this study is to survey the effect of Tamoxifen in motor neuron disease (MND) patients, amyotrophic lateral sclerosis (ALS) with regular riluzole usage. TDP-43 is related to ALS.
- Conditions
- Amyotrophic Lateral Sclerosis, ALS Functional Ration Scale, TAR-DNA-binding Protein-43, Tamoxifen
- Trial name
- NCT02166944
- Testing
- tamoxifen 40 mg daily for one year
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Taipei Medical University Shuang Ho Hospital
Amyotrophic Lateral Sclerosis
Predictive Factors for the Diagnosis of Early Noninvasive Ventilation Equipment
To compensate for insufficiency of diagnostic tools, the present study propose to look for the predictive factors of an early fitting by noninvasive ventilation.
- Trial name
- PREDAPP (NCT03452618)
- Testing
- diagnosis variables
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Toulouse
Amyotrophic Lateral Sclerosis
Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS)
The first questions asked by patients with a new diagnosis of Amyotrophic Lateral Sclerosis (ALS) often include: "Does exercise help slow the progression of the disease?", "Is there any harm in exercising?", or "What type of…
- Trial name
- NCT01521728
- Testing
- Resistance Exercise, Endurance Exercise, Stretching/Range-of-Motion
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Johns Hopkins University
Amyotrophic Lateral Sclerosis, Dysphagia
Fatigue in Patients With Amyotrophic Lateral Sclerosis
Expiratory muscle strength training (EMST) is an emerging palliative intervention for prolonging pulmonary and swallow function in patients with amyotrophic lateral sclerosis (PALS), but it is unknown whether EMST may result in…
- Conditions
- Amyotrophic Lateral Sclerosis, Dysphagia, Dyspnea, Respiration Disorders
- Trial name
- NCT04468191
- Testing
- Experimental expiratory muscle strength training (EMST)
- Where
- United States
- Sponsor
- Cara Donohue
Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System
A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).
The main purpose of this study in participants with Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS) is to test the safety of different doses and to determine the amount of LY3873862 that gets into the bloodstream and how…
- Trial name
- NCT07883590
- Testing
- LY3873862, CYP450 Drug Cocktail
- Where
- 4 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Amyotrophic Lateral Sclerosis, Neurodegenerative Disease
Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population
New technologies are giving people with motor disabilities alternative communication and control channels. The investigators are interested in using the Cyberlink Control System as a hands free means to access a computer for…
- Conditions
- Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
- Trial name
- NCT00718497
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Drexel University College of Medicine
Amyotrophic Lateral Sclerosis
Polish Version Dyspnea in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis is a fatal disease with progressive degeneration of central and peripheral motor neurons. Weakness of pharyngeal and respiratory muscles lead to dyspnea, which is present in up to 80% of patients.
- Trial name
- NCT07178574
- Volunteers
- 120 people
- Sponsor
- Jakub Antczak
Amyotrophic Lateral Sclerosis
Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls
The purpose of this study is to study the transporters of serotonin and dopamine in ALS patients in relation with the clinical phenotype, i.e., patients without stiffness, patients with pyramidal stiffness, patients with mixed…
- Trial name
- DOSERAL (NCT01160263)
- Testing
- SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
- Where
- 2 sites in France
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Staphylococcus Aureus
Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization
The proposed study aims to further evaluate the safety and immunogenicity of a candidate S. aureus vaccine NDV-3A, as well as its efficacy against acquisition of S. aureus
- Trial name
- NCT03455309
- Testing
- NDV-3A
- Where
- United States
- Volunteers
- 382 people, healthy volunteers welcome
- Sponsor
- NovaDigm Therapeutics, Inc.
Asthma, Atrial Fibrillation
The Living With a Long-Term Condition Study
Psychological distress (anxiety and depression) is common in and experienced differently by people living with long-term health conditions (LTCs).
- Conditions
- Asthma, Atrial Fibrillation, Cancer, Cerebrovascular Disorders
- Trial name
- LTC (NCT06072287)
- Testing
- Living with LTC Questionnaire
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- King's College London